Cochrane · systematic review · CD003753
Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis
Macfarlane, CL, Budhathoki, SS, Johnson, S, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
Infectious DiseasesAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
28
current version
GRADE rated
26
No studies
2
Included studies
NR
No studies 2 · 7.1%Ungraded 0 · 0%Very low 9 · 32.1%Low 5 · 17.9%Moderate 4 · 14.3%High 8 · 28.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Albendazole alone or added to a microfilaricidal drug for lymphatic filariasis
Population: people with lymphatic filariasis or communities where lymphatic filariasis is endemic
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Microfilaraemia (mf) prevalence | RR 0.95 [0.85, 1.07] | 12 studies · 5027 participants | High |
Mf density | no estimate extracted | 10 studies · 1216 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Mf density | no estimate extracted | 9 studies · 1052 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Antigenaemia prevalence | RR 1.04 [0.97, 1.12] | 7 studies · 3774 participants | High |
Antigen density | no estimate extracted | 5 studies · 1374 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Adult worm prevalence detected by ultrasound | RR 1.16 [0.72, 1.86] | 3 studies · 165 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Adverse events | RR 0.97 [0.84, 1.13] | 6 studies · 2894 participants | High |
Albendazole alone for lymphatic filariasis
Population: people with lymphatic filariasis or communities where lymphatic filariasis is endemic
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Microfilaraemia (mf) prevalence | RR 0.98 [0.81, 1.19] | 4 studies · 1406 participants | High |
Mf density | no estimate extracted | 4 studies · 285 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Mf density | no estimate extracted | 2 studies · 169 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Antigenaemia prevalence | RR 1.07 [0.91, 1.25] | 2 studies · 1054 participants | High |
Antigen density | no estimate extracted | 2 studies · 371 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Adult worm prevalence detected by ultrasound ‐ not measured | no estimate extracted | NR | No studies |
Adverse events | RR 0.95 [0.61, 1.48] | 2 studies · 678 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Albendazole added to DEC for lymphatic filariasis
Population: people with lymphatic filariasis or communities where lymphatic filariasis is endemic
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Microfilaraemia (mf) prevalence | RR 0.9 [0.75, 1.09] | 7 studies · 1102 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Mf density | no estimate extracted | 6 studies · 559 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Mf density | no estimate extracted | 6 studies · 535 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Antigenaemia prevalence | RR 1.03 [0.92, 1.14] | 5 studies · 954 participants | High |
Antigen density | no estimate extracted | 3 studies · 270 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Adult worm prevalence detected by ultrasound | RR 1.16 [0.72, 1.86] | 3 studies · 165 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Adverse events | RR 0.94 [0.79, 1.11] | 4 studies · 1589 participants | High |
Albendazole added to ivermectin for lymphatic filariasis
Population: people with lymphatic filariasis or communities where lymphatic filariasis is endemic
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Microfilaraemia (mf) prevalence | RR 0.84 [0.54, 1.31] | 4 studies · 2519 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Mf density | no estimate extracted | 3 studies · 372 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Mf density | no estimate extracted | 2 studies · 348 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Antigenaemia prevalence | RR 1.04 [0.94, 1.16] | 2 studies · 1766 participants | High |
Antigen density | no estimate extracted | 2 studies · 733 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Adult worm prevalence detected by ultrasound ‐ not measured | no estimate extracted | NR | No studies |
Adverse events | RR 1.16 [0.77, 1.74] | 1 study · 627 participants | Moderate Downgraded: risk of bias, imprecision |